RV Group, an ASEAN and CIS-region pharmaceutical leader with over 3,500 employees across nine countries, has announced its entry into the Indian market with the acquisition of GSK’s legacy brands Celin and Septran. This strategic move, facilitated through a merger with KCH, aims to strengthen the company’s position in India’s flourishing pharmaceutical sector, which is currently focused on developing R&D capabilities and targeting exports to European and US markets. Rajiv Sharma, Chairman and Founder of RV Group, highlighted the importance of a strong front-end operation in India to make a significant impact on the market. With this acquisition, RV Group aims to leverage KCH’s operational expertise and established brand recognition. Additionally, RV Group is planning to introduce nutraceutical products in India, starting in states like Bihar and West Bengal, to cater to the shifting consumer focus from illness to wellness. The acquisition is also part of RV Group’s broader expansion strategy that includes entering the US market next year. This move underscores the company’s commitment to providing high-quality, affordable healthcare solutions globally.

Pharmaceuticals, Nutraceuticals,India, ASEAN, United States